Combination comprising an omega-3 fatty acid composition and an sglt2 inhibitor
AssigneeAstraZeneca AB
InventorKarl Erik, Goeran GANNEDAHL
Life of this patent
Estimating the term…
Abstract
A method for treating NAFLD and/or NASH and suitable compositions for carrying out the method are claimed.
Claims21
A combination of an effective dose of an omega-3 fatty acid composition wherein the omega-3 fatty acid composition contains one or more omega-3 fatty acids which may be present as acids, esters, triglycerides, phospholipids or salts and an effective dose of an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a prodrug ester thereof, for in the treatment of non-alcoholic steatohepatitis (NASH) in a subject having, or suspected of having, NASH.
A combination of an effective dose of Epanova® or a bioequivalent version thereof and an effective dose of canagliflozin or ipragliflozin, for use in the reduction of liver fat in a subject who has been diagnosed with Type II diabetes mellitus and diagnosed as having raised liver fat.
12-16. (canceled)
A combination of Epanova® or a bioequivalent version thereof and canagliflozin or ipragliflozin.
Dependencies are inferred from the claim text.